Drug intelligence / Profile preview

LE-AD-101

Development stage: Preclinical
Lead developer: Akrocell Biosciences
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

LE-AD-101 is a canine mesenchymal stem cell (MSC)-derived exosome therapeutic under development by Akrocell Biosciences for the treatment of canine atopic dermatitis. It leverages the immunomodulatory and anti-inflammatory properties of species-specific exosomes to address the underlying immune dysregulation associated with chronic, relapsing inflammatory skin disease in dogs. LE-AD-101 is currently in preclinical development.

Beyond the preview

Go deeper on LE-AD-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LE-AD-101.

Explore the full profile